

Tim M Illidge

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8708859/tim-m-illidge-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

194
papers

10,477
citations

50
h-index

99
g-index

218
ext. papers

12,634
ext. citations

4.7
avg, IF

5.96
L-index

#	Paper	IF	Citations
194	Pretreatment Lymphocyte Count Predicts Benefit From Concurrent Chemotherapy With Radiotherapy in Oropharyngeal Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2101991	2.2	0
193	The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 135-135	2.2	1
192	Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2021 ,	4.5	0
191	4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , 2021 , 22, 332-340	21.7	13
190	Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. <i>Clinical Cancer Research</i> , 2021 , 27, 4353-4366	12.9	6
189	Immunomodulation by radiotherapy in tumour control and normal tissue toxicity. <i>Nature Reviews Immunology</i> , 2021 ,	36.5	14
188	Radiotherapy-Immunotherapy Combination: How Will We Bridge the Gap Between Pre-Clinical Promise and Effective Clinical Delivery?. <i>Cancers</i> , 2021 , 13,	6.6	12
187	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3591-3601	2.2	1
186	Progress and pitfalls with the use of image-guided personalised approaches in lymphoma. <i>British Journal of Radiology</i> , 2021 , 94, 20210609	3.4	1
185	Reprogramming the tumour microenvironment by radiotherapy: implications for radiotherapy and immunotherapy combinations. <i>Radiation Oncology</i> , 2020 , 15, 254	4.2	16
184	Toll-Like Receptor Agonists and Radiation Therapy Combinations: An Untapped Opportunity to Induce Anticancer Immunity and Improve Tumor control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 27-37	4	6
183	ILROG emergency guidelines for radiation therapy of hematological malignancies during the COVID-19 pandemic. <i>Blood</i> , 2020 , 135, 1829-1832	2.2	50
182	The investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2020 , 191, 363-381	4.5	5
181	Involved Site Radiation Therapy in Adult Lymphomas: An Overview of International Lymphoma Radiation Oncology Group Guidelines. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 107, 909-933	4	26
180	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death 2020 , 8,		233
179	Understanding the Effects of Radiotherapy on the Tumour Immune Microenvironment to Identify Potential Prognostic and Predictive Biomarkers of Radiotherapy Response. <i>Cancers</i> , 2020 , 12,	6.6	5
178	Is it time to rethink checkpoint blockade therapy in non-Hodgkin lymphoma?. <i>British Journal of Haematology</i> , 2020 , 191, 13-14	4.5	1

177	Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 4091-4101	7.8	13
176	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020 , 4, 203-206	7.8	10
175	Evaluation of apoptosis imaging biomarkers in a genetic model of cell death. <i>EJNMMI Research</i> , 2019 , 9, 18	3.6	9
174	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1732-1741	2.2	26
173	Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma. <i>International Reviews of Immunology</i> , 2019 , 38, 79-91	4.6	2
172	Immunogenic Effects of Radiotherapy for Bladder Cancer. <i>Clinical Oncology</i> , 2019 , 31, e26	2.8	
171	Scientific rationale underpinning the development of biosimilar rituximab in hematological cancers and inflammatory diseases. <i>Future Oncology</i> , 2019 , 15, 4223-4234	3.6	4
170	CLINICAL OUTCOMES ASSOCIATED WITH THE TREATMENT OF NEWLY DIAGNOSED STAGE IV CLASSICAL HODGKIN LYMPHOMA IN PRACTICE SETTINGS IN FRANCE, GERMANY AND THE UNITED KINGDOM. <i>Hematological Oncology</i> , 2019 , 37, 488-490	1.3	
169	British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. <i>British Journal of Dermatology</i> , 2019 , 180, 496-526 ⁴		55
168	The management of primary mediastinal B-cell lymphoma: a British Society for Haematology Good Practice Paper. <i>British Journal of Haematology</i> , 2019 , 185, 402-409	4.5	7
167	Clinical Development of Novel Drug-Radiotherapy Combinations. <i>Clinical Cancer Research</i> , 2019 , 25, 1455-1461 ²⁵	2.1	25
166	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019 , 393, 229-240	4.0	283
165	Patient and physician preferences for first-line treatment of classical Hodgkin lymphoma in Germany, France and the United Kingdom. <i>British Journal of Haematology</i> , 2019 , 184, 202-214	4.5	11
164	Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. <i>Blood</i> , 2018 , 131, 2120-2124	2.2	39
163	The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 1100-1118	4	25
162	Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 652-669	4	41
161	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. <i>Annals of Oncology</i> , 2018 , 29, 301-310	10.3	56
160	Recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 1069-1070	10.3	2

159	Real-world effectiveness of brentuximab vedotin versus physicians' choice chemotherapy in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplantation in the United Kingdom and Germany. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1413-1419	1.9	10
158	The anti-PD-1 era - an opportunity to enhance radiotherapy for patients with bladder cancer. <i>Nature Reviews Urology</i> , 2018 , 15, 251-259	5.5	15
157	Revisiting the role of radiotherapy in Hodgkin lymphoma to augment systemic immunity. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2519-2520	1.9	
156	LYMRIT 37-01: A Phase I/II Study of ¹⁷⁷ Lu-Lilotomab Satetraxetan (Betalutin [®]) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) [Analysis with 6-Month Follow-up. <i>Blood</i> , 2018 , 132, 2879-2879	2.2	6
155	The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas. <i>Blood</i> , 2018 , 132, 997-997	2.2	1
154	Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2018 , 29, iv19-iv29	10.3	142
153	Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?. <i>Clinical Oncology</i> , 2017 , 29, 207-217	2.8	5
152	A TLR7 agonist enhances the antitumor efficacy of obinutuzumab in murine lymphoma models via NK cells and CD4 T cells. <i>Leukemia</i> , 2017 , 31, 1611-1621	10.7	23
151	Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade. <i>Clinical Cancer Research</i> , 2017 , 23, 5514-5526	12.9	195
150	Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. <i>Blood</i> , 2017 , 130, 2709-2717	2.2	121
149	Brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma who are Ineligible for autologous stem cell transplant: A Germany and United Kingdom retrospective study. <i>European Journal of Haematology</i> , 2017 , 99, 553-558	3.8	10
148	Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment. <i>EMBO Molecular Medicine</i> , 2017 , 9, 1646-1659	12	11
147	The influence of radiation in the context of developing combination immunotherapies in cancer 2017 , 5, 115-122	2.6	9
146	Stereotactic ablative radiotherapy and immunotherapy combinations: turning the future into systemic therapy?. <i>British Journal of Radiology</i> , 2016 , 89, 20160472	3.4	28
145	Immunotherapy with radiotherapy in urological malignancies. <i>Current Opinion in Urology</i> , 2016 , 26, 514-228		5
144	Antitumor Efficacy of Radiation plus Immunotherapy Depends upon Dendritic Cell Activation of Effector CD8+ T Cells. <i>Cancer Immunology Research</i> , 2016 , 4, 621-630	12.5	42
143	Clinical development of new drug-radiotherapy combinations. <i>Nature Reviews Clinical Oncology</i> , 2016 , 13, 627-42	19.4	162
142	¹⁷⁷ Lu-Satetraxetan-Lilotomab in the Treatment of Patients with Indolent Non-Hodgkin B-Cell Lymphoma (NHL), Phase 1/2 Safety and Efficacy Data from Four Different Pre-Dosing Regimens. <i>Blood</i> , 2016 , 128, 1780-1780	2.2	1

141	Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas. <i>Blood</i> , 2016 , 128, 2993-2993	2.2	5
140	Five-Year Survival Data from a Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2016 , 128, 4144-4144	2.2	8
139	Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. <i>Oncotarget</i> , 2016 , 7, 17035-46	3.3	18
138	Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study. <i>British Journal of Haematology</i> , 2016 , 173, 274-82	4.5	11
137	Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2016 , 27, v91-v102	10.3	69
136	Re-Examining the Role of Radiation Therapy for Diffuse Large B-Cell Lymphoma in the Modern Era. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1443-7	2.2	24
135	Improving therapeutic activity of anti-CD20 antibody therapy through immunomodulation in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1269-80	1.9	4
134	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. <i>Clinical Oncology</i> , 2016 , 28, 726-731	2.8	6
133	Guidelines for the management of diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , 2016 , 174, 43-56	4.5	84
132	Radiation therapy planning for early-stage Hodgkin lymphoma: experience of the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 144-52	4	16
131	Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 32-9	4	96
130	Personalised approach to treating early Hodgkin's lymphoma. <i>BMJ, The</i> , 2015 , 350, h2927	5.9	2
129	Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 11-31	4	211
128	Immuno-regulatory antibodies for the treatment of cancer. <i>Expert Opinion on Biological Therapy</i> , 2015 , 15, 787-801	5.4	36
127	Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. <i>New England Journal of Medicine</i> , 2015 , 372, 1598-607	59.2	437
126	PET-Directed Therapy for Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015 , 373, 392	59.2	15
125	Obinutuzumab in hematologic malignancies: lessons learned to date. <i>Cancer Treatment Reviews</i> , 2015 , 41, 784-92	14.4	37
124	The antitumor immune response generated by fractionated radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade. <i>OncImmunology</i> , 2015 , 4, e1016709	7.2	56

123	Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 703-10	1.9	25
122	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. <i>Cancer Treatment Reviews</i> , 2015 , 41, 503-10	14.4	369
121	Frontline Treatment of CD30+ Peripheral T-Cell Lymphomas with Brentuximab Vedotin in Combination with CHP: 3-Year Durability and Survival Follow-up. <i>Blood</i> , 2015 , 126, 1537-1537	2.2	5
120	Emerging opportunities for the combination of molecularly targeted drugs with radiotherapy. <i>Clinical Oncology</i> , 2014 , 26, 266-76	2.8	11
119	A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models. <i>International Journal of Cancer</i> , 2014 , 135, 820-9	7.5	30
118	Update on obinutuzumab in the treatment of B-cell malignancies. <i>Expert Opinion on Biological Therapy</i> , 2014 , 14, 1507-17	5.4	15
117	Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014 , 25 Suppl 3, iii70-5	10.3	127
116	Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. <i>Cancer Research</i> , 2014 , 74, 5458-68	10.1	704
115	Fractionated α -ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria. <i>Journal of Clinical Oncology</i> , 2014 , 32, 212-8	2.2	50
114	Radiation Therapy Induces an Adaptive Upregulation of PD-L1 on Tumor Cells Which May Limit the Efficacy of the Anti-Tumor Immune Response But Can Be Circumvented by Anti-PD-L1. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 90, S776	4	9
113	Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 49-58	4	185
112	Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 854-62	4	350
111	Consensus guidelines for the detection of immunogenic cell death. <i>Oncotarget</i> , 2014 , 3, e955691	7.2	524
110	Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and S \ddot{a} ry syndrome). <i>Annals of Oncology</i> , 2014 , 25, 1807-1812	10.3	32
109	New opportunities for anti-CD20 monoclonal antibody to give a direct punch to the tumor. <i>Leukemia and Lymphoma</i> , 2014 , 55, 3-4	1.9	1
108	Risk of premature menopause after treatment for Hodgkin's lymphoma. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	37
107	Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014 , 164, 39-52	4.5	22
106	Comment on: "clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 Study)". <i>Oncologist</i> , 2014 , 19, 1289	5.7	0

105	Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3137-43	2.2	127
104	4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. <i>Lancet Oncology</i> , 2014 , 15, 457-63	21.7	142
103	Four-Year Survival Data from an Ongoing Pivotal Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3095-3095	2.2	13
102	Abstract 5034: The antitumor immune response generated by radiation therapy may be limited by tumor cell adaptive resistance and can be circumvented by PD-L1 blockade 2014 ,		2
101	Immunogenic potential of irradiated lymphoma cells is enhanced by adjuvant immunotherapy and modulation of local macrophage populations. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2008-15	1.9	11
100	Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma. <i>Blood</i> , 2013 , 121, 251-9	2.2	109
99	U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. <i>British Journal of Dermatology</i> , 2013 , 168, 192-200	4	64
98	Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response. <i>Cell Death and Differentiation</i> , 2013 , 20, 765-73	12.7	17
97	Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2531-3	1.9	93
96	Breast cancer risk following Hodgkin lymphoma radiotherapy in relation to menstrual and reproductive factors. <i>British Journal of Cancer</i> , 2013 , 108, 2399-406	8.7	39
95	The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab. <i>British Journal of Haematology</i> , 2013 , 162, 842-5	4.5	14
94	XVII. Radiotherapy in early stage Hodgkin lymphoma. <i>Hematological Oncology</i> , 2013 , 31 Suppl 1, 92-5	1.3	4
93	Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma. <i>British Journal of Cancer</i> , 2013 , 109, 2566-73	8.7	28
92	A study to investigate dose escalation of doxorubicin in ABVD chemotherapy for Hodgkin lymphoma incorporating biomarkers of response and toxicity. <i>British Journal of Cancer</i> , 2013 , 109, 2560-5	8.7	6
91	Synchronous apoptosis in established tumors leads to the induction of adaptive immunity. <i>Onc Immunology</i> , 2013 , 2, e24501	7.2	4
90	Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. <i>Haematologica</i> , 2013 , 98, 611-4	6.6	81
89	Three-Year Survival Results From An Ongoing Phase 2 Study Of Brentuximab Vedotin In Patients With Relapsed Or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2013 , 122, 1809-1809	2.2	20
88	Brentuximab Vedotin Administered Before, During, and After Multi-Agent Chemotherapy In Patients (pts) With Newly-Diagnosed CD30+ Mature T- and NK-Cell Lymphomas. <i>Blood</i> , 2013 , 122, 4386-4386	2.2	5

87	Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. <i>Blood</i> , 2012 , 119, 3523-33	2.2	92
86	Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2190-6	2.2	759
85	Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2012 , 159, 541-64	4.5	89
84	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012 , 156, 446-67	4.5	49
83	Radiotherapy physics research in the UK: challenges and proposed solutions. <i>British Journal of Radiology</i> , 2012 , 85, 1354-62	3.4	8
82	Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma. <i>Blood and Lymphatic Cancer: Targets and Therapy</i> , 2012 , 99	2.6	
81	Long-Term Remissions Observed in an Ongoing Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma.. <i>Blood</i> , 2012 , 120, 2745-2745	2.2	3
80	Overall Survival Benefit for Patients with Relapsed Hodgkin Lymphoma Treated with Brentuximab Vedotin After Autologous Stem Cell Transplant. <i>Blood</i> , 2012 , 120, 3701-3701	2.2	6
79	Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy As Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell Lymphomas. <i>Blood</i> , 2012 , 120, 60-60	2.2	6
78	New antibody drug treatments for lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 623-40	5.4	12
77	Radioimmunotherapy in follicular lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2011 , 24, 279-93	4.2	26
76	Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. <i>Radiotherapy and Oncology</i> , 2011 , 100, 86-92	5.3	226
75	Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. <i>Blood</i> , 2011 , 117, 4519-29	2.2	234
74	The future of anti-CD20 monoclonal antibodies: are we making progress?. <i>Blood</i> , 2011 , 117, 2993-3001	2.2	102
73	Assessment of circulating biomarkers for potential pharmacodynamic utility in patients with lymphoma. <i>British Journal of Cancer</i> , 2011 , 104, 719-25	8.7	36
72	X. When should radiotherapy be used in lymphoma?. <i>Annals of Oncology</i> , 2011 , 22, iv57-iv60	10.3	1
71	YY1 expression predicts favourable outcome in follicular lymphoma. <i>Journal of Clinical Pathology</i> , 2011 , 64, 125-9	3.9	25
70	Tumor cell embryonality and the ploidy number 32n: is it a developmental checkpoint?. <i>Cell Cycle</i> , 2011 , 10, 1873-4	4.7	7

69	Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. <i>British Journal of Cancer</i> , 2011 , 105, 628-39	8.7	110
68	Rituximab Cerebrospinal Fluid Levels in Patients with Primary Central Nervous System Lymphoma Treated with Intravenous High Dose Rituximab. <i>Blood</i> , 2011 , 118, 1644-1644	2.2	8
67	Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas. <i>Blood</i> , 2011 , 118, 3091-3091	2.2	6
66	Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma: A Phase 2 Study Update. <i>Blood</i> , 2011 , 118, 443-443	2.2	10
65	Antibody-Induced Non-Apoptotic Cell Death in Human Lymphoma and Leukemia Cells Is Mediated Through NADPH Oxidase-Derived Reactive Oxygen Species. <i>Blood</i> , 2011 , 118, 1651-1651	2.2	
64	Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2944-6	2.2	31
63	A retrospective analysis of selective internal radiation therapy (SIRT) with yttrium-90 microspheres in patients with unresectable hepatic malignancies. <i>Clinical Radiology</i> , 2010 , 65, 720-8	2.9	8
62	Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates. <i>Blood</i> , 2010 , 116, 3373-3374	2.2	8
61	Validation of an ELISA for the determination of rituximab pharmacokinetics in clinical trials subjects. <i>Journal of Immunological Methods</i> , 2010 , 360, 30-8	2.5	21
60	Complete Remissions with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2010 , 116, 961-961	2.2	11
59	Anti-HLA-DR Monoclonal Antibody Evokes a Novel Non-Apoptotic Cell Death Pathway In Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010 , 116, 3245-3245	2.2	
58	Safety and Efficacy of I(131) Tositumomab in the Treatment of non-Hodgkin's Lymphoma. <i>Clinical Medicine Therapeutics</i> , 2009 , 1, CMT.S2124		
57	Radioimmunotherapy: strategies for the future in indolent and aggressive lymphoma. <i>Current Oncology Reports</i> , 2009 , 11, 363-70	6.3	4
56	Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. <i>Blood</i> , 2009 , 113, 1412-21	2.2	75
55	When is a predose a dose too much?. <i>Blood</i> , 2009 , 113, 6034-5	2.2	4
54	Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. <i>Journal of Clinical Investigation</i> , 2009 , 119, 2143-59	15.9	134
53	New-Generation Anti-CD20 Monoclonal Antibody (GA101) Evokes Homotypic Adhesion and Actin-Dependent, Lysosome-Mediated Cell Death in B-Cell Lymphoma.. <i>Blood</i> , 2009 , 114, 725-725	2.2	3
52	New insights into the mechanisms of action of radioimmunotherapy in lymphoma. <i>Journal of Pharmacy and Pharmacology</i> , 2008 , 60, 987-98	4.8	2

51	How have outcomes for patients with follicular lymphoma changed with the addition of monoclonal antibodies?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1263-73	1.9	7
50	Consensus conference: implementing treatment recommendations on yttrium-90 immunotherapy in clinical practice - report of a European workshop. <i>European Journal of Cancer</i> , 2008 , 44, 366-73	7.5	24
49	Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. <i>Clinical Cancer Research</i> , 2008 , 14, 4925-34	12.9	28
48	Current treatment approaches for diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 663-76	1.9	18
47	Clinical quantitation of immune signature in follicular lymphoma by RT-PCR-based gene expression profiling. <i>Blood</i> , 2008 , 111, 4764-70	2.2	79
46	Endopolyploidy in irradiated p53-deficient tumour cell lines: persistence of cell division activity in giant cells expressing Aurora-B kinase. <i>Cell Biology International</i> , 2008 , 32, 1044-56	4.5	56
45	Novel Mechanisms of Non-Apoptotic Cell Death Evoked by Type II Anti-CD20 (Tositumomab) and HLA-DR Monoclonal Antibodies. <i>Blood</i> , 2008 , 112, 883-883	2.2	1
44	A Blood Borne Biomarker of Cell Death (nucleosomal DNA) Is An Early Predictor of End of Treatment Response to Chemotherapy in Lymphoma. <i>Blood</i> , 2008 , 112, 4828-4828	2.2	
43	Microscopic intratumoral dosimetry of radiolabeled antibodies is a critical determinant of successful radioimmunotherapy in B-cell lymphoma. <i>Cancer Research</i> , 2007 , 67, 1335-43	10.1	10
42	Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3440-7	2.2	135
41	Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. <i>Blood</i> , 2007 , 109, 4655-62	2.2	168
40	Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. <i>Blood</i> , 2007 , 110, 54-8	2.2	156
39	Clinical Measurement of Prognostic Immune Signature in Follicular Lymphoma by RT-PCR Based Gene Expression Profiling and Immunohistochemistry Demonstrates Favourable T-Cell and Unfavorable Macrophage Infiltration.. <i>Blood</i> , 2007 , 110, 359-359	2.2	
38	Upregulation of meiosis-specific genes in lymphoma cell lines following genotoxic insult and induction of mitotic catastrophe. <i>BMC Cancer</i> , 2006 , 6, 6	4.8	70
37	Recommendations for the use of yttrium-90 ibritumomab tiuxetan in malignant lymphoma. <i>Cancer</i> , 2006 , 107, 686-95	6.4	30
36	A50 iodogen labelling method preserves immunoreactivity of high specific activity 131I-labelled rituximab for clinical RIT. <i>Nuclear Medicine Communications</i> , 2006 , 27, 293-294	1.6	
35	Macrophage Depletion Can Enhance Combined Radiation and Anti-CD40 Monoclonal Antibody Therapy of B-Cell Lymphoma.. <i>Blood</i> , 2006 , 108, 2501-2501	2.2	
34	Treatment with the Anti-CD20 Antibody (B1) and Irradiation Result in Synergistic Cytotoxicity That Is Dependent on MAPK Activation.. <i>Blood</i> , 2006 , 108, 2508-2508	2.2	

33	Anti-CD 40 monoclonal antibody. <i>Leukemia and Lymphoma</i> , 2005 , 46, 1105-13	1.9	21
32	Anti-CD40: Janus or gatekeeper?. <i>Blood</i> , 2005 , 106, 2595-2596	2.2	1
31	Segregation of genomes in polyploid tumour cells following mitotic catastrophe. <i>Cell Biology International</i> , 2005 , 29, 1005-11	4.5	84
30	What's new in the management of cutaneous T-cell lymphoma?. <i>Clinical Oncology</i> , 2005 , 17, 174-84	2.8	10
29	Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. <i>Cancer Research</i> , 2005 , 65, 7493-501	10.1	9
28	Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 157-65	2.2	441
27	Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004 , 125, 294-317	4.5	112
26	Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. <i>Blood</i> , 2004 , 103, 1485-94	2.2	18
25	Apparent modulation of CD20 by rituximab: an alternative explanation. <i>Blood</i> , 2004 , 103, 3989-90; author reply 3990-1	2.2	19
24	A new anti-idiotypic antibody capable of binding rituximab on the surface of lymphoma cells. <i>Blood</i> , 2004 , 104, 2540-2	2.2	39
23	Phase I/II Study of Fractionated Radioimmunotherapy (RIT) in Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL).. <i>Blood</i> , 2004 , 104, 131-131	2.2	2
22	Cyclophosphamide Induced CD11b+ Cells Can Inhibit Anti-CD40 Monoclonal Antibody (mAb) Therapy of B-Cell Lymphoma.. <i>Blood</i> , 2004 , 104, 3280-3280	2.2	
21	Endopolyploid cells produced after severe genotoxic damage have the potential to repair DNA double strand breaks. <i>Journal of Cell Science</i> , 2003 , 116, 4095-106	5.3	80
20	Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. <i>Blood</i> , 2003 , 102, 1449-57	2.2	73
19	Nuclear envelope-limited chromatin sheets are part of mitotic death. <i>Histochemistry and Cell Biology</i> , 2002 , 117, 243-55	2.4	30
18	Cervical neuropathy following mantle radiotherapy. <i>Clinical Oncology</i> , 2002 , 14, 468-71	2.8	13
17	Trastuzumab: designer drug or fashionable fad?. <i>Clinical Oncology</i> , 2001 , 13, 427-33	2.8	1
16	Antibody therapy of lymphoma. <i>Expert Opinion on Pharmacotherapy</i> , 2001 , 2, 953-61	4	11

15	Hypercalcaemia, Parathyroid Hormone-Related Protein and Malignancy. <i>Clinical Oncology</i> , 2001 , 13, 372-387	2
14	Release of mitotic descendants by giant cells from irradiated Burkitt's lymphoma cell line. <i>Cell Biology International</i> , 2000 , 24, 635-48	4.5 77
13	The emerging role of radioimmunotherapy in haematological malignancies. <i>British Journal of Haematology</i> , 2000 , 108, 679-88	4.5 25
12	A new in vivo and in vitro B cell lymphoma model, pi-BCL1. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000 , 15, 571-80	3.9 13
11	Radioimmunotherapy in the pi-BCL1 B cell lymphoma model: efficacy depends on more than targeted irradiation alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000 , 15, 581-91	3.9 9
10	Polyploid giant cells provide a survival mechanism for p53 mutant cells after DNA damage. <i>Cell Biology International</i> , 2000 , 24, 621-33	4.5 107
9	Radioimmunotherapy of cancer: using monoclonal antibodies to target radiotherapy. <i>Current Pharmaceutical Design</i> , 2000 , 6, 1399-418	3.3 21
8	The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma. <i>Blood</i> , 1999 , 94, 233-243	2.2 24
7	The future of oncology training: from the trainees' perspective. <i>Clinical Oncology</i> , 1998 , 10, 84-91	2.8 6
6	Radiation-induced apoptosis. <i>Clinical Oncology</i> , 1998 , 10, 3-13	2.8 11
5	Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate. <i>Clinical Oncology</i> , 1996 , 8, 257-8	2.8 56
4	Arthritis and carcinoma. <i>Annals of the Rheumatic Diseases</i> , 1993 , 52, 86	2.4 3
3	Euthanasia. <i>BMJ: British Medical Journal</i> , 1992 , 305, 1225	1
2	Effect of dihydroxy-bile salts on the interaction of trypsin and trypsin inhibitors. <i>Biochemical Society Transactions</i> , 1988 , 16, 168-168	5.1
1	Treatment of Cancer	14